Markus Wahrmann

3.1k total citations
70 papers, 2.1k citations indexed

About

Markus Wahrmann is a scholar working on Transplantation, Immunology and Nephrology. According to data from OpenAlex, Markus Wahrmann has authored 70 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Transplantation, 47 papers in Immunology and 25 papers in Nephrology. Recurrent topics in Markus Wahrmann's work include Renal Transplantation Outcomes and Treatments (53 papers), Complement system in diseases (39 papers) and Renal Diseases and Glomerulopathies (25 papers). Markus Wahrmann is often cited by papers focused on Renal Transplantation Outcomes and Treatments (53 papers), Complement system in diseases (39 papers) and Renal Diseases and Glomerulopathies (25 papers). Markus Wahrmann collaborates with scholars based in Austria, Canada and Germany. Markus Wahrmann's co-authors include Georg A. Böhmig, Heinz Regele, Markus Exner, Farsad Eskandary, Gregor Bartel, Walter H. Hörl, Gregor Bond, Günther F. Körmöczi, Gerhard J. Zlabinger and Philip F. Halloran and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Scientific Reports.

In The Last Decade

Markus Wahrmann

69 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Markus Wahrmann Austria	28	1.7k	940	875	640	233	70	2.1k
Caroline Suberbielle‐Boissel France	17	1.9k 1.1×	630 0.7×	1.1k 1.3×	658 1.0×	219 0.9×	24	2.2k
Joseph Kahwaji United States	20	1.3k 0.8×	544 0.6×	701 0.8×	432 0.7×	253 1.1×	43	1.8k
Annette M. Jackson United States	24	1.2k 0.7×	601 0.6×	772 0.9×	474 0.7×	144 0.6×	85	1.8k
Lorita M. Rebellato United States	17	1.2k 0.7×	607 0.6×	760 0.9×	337 0.5×	164 0.7×	43	1.6k
Jessica Chang Canada	24	1.9k 1.1×	626 0.7×	1.2k 1.3×	600 0.9×	357 1.5×	43	2.4k
Kazuya Omoto Japan	22	865 0.5×	404 0.4×	576 0.7×	221 0.3×	169 0.7×	120	1.4k
Yoshihiko Watarai Japan	21	799 0.5×	277 0.3×	570 0.7×	401 0.6×	253 1.1×	141	1.6k
G. Mogilishetty United States	15	918 0.5×	340 0.4×	511 0.6×	275 0.4×	125 0.5×	30	1.3k
Waichi Wong United States	15	816 0.5×	531 0.6×	539 0.6×	125 0.2×	149 0.6×	23	1.4k
D. Phelan United States	26	1.1k 0.6×	474 0.5×	1.3k 1.5×	140 0.2×	216 0.9×	65	1.9k

Countries citing papers authored by Markus Wahrmann

Since Specialization

Citations

This map shows the geographic impact of Markus Wahrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Wahrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Wahrmann more than expected).

Fields of papers citing papers by Markus Wahrmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Wahrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Wahrmann. The network helps show where Markus Wahrmann may publish in the future.

Co-authorship network of co-authors of Markus Wahrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Wahrmann. A scholar is included among the top collaborators of Markus Wahrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Wahrmann. Markus Wahrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mühlbacher, Jakob, et al.. (2025). COVID-19 mRNA-1273 vaccination induced mast cell activation with strongly elevated Th2 cytokines in a systemic mastocytosis patient. Inflammation Research. 74(1). 71–71. 1 indexed citations

Mühlbacher, Jakob, Farsad Eskandary, Martin Schiemann, et al.. (2024). Torque Teno Virus Control by the Classical Pathway of Complement Activation—A Retrospective Analysis From a First‐in‐Human Trial Utilizing Sutimlimab. Journal of Medical Virology. 96(11). e70039–e70039. 2 indexed citations

Vondra, Sigrid, Johanna Raffetseder, Andrea Vogel, et al.. (2023). The human placenta shapes the phenotype of decidual macrophages. Cell Reports. 42(1). 111977–111977. 21 indexed citations

Mayer, Katharina A., Klemens Budde, Philip F. Halloran, et al.. (2022). Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial. Trials. 23(1). 270–270. 15 indexed citations

Vietzen, Hannes, Bernd Döhler, Thuong Hien Tran, et al.. (2022). Deletion of the Natural Killer Cell Receptor NKG2C Encoding KLR2C Gene and Kidney Transplant Outcome. Frontiers in Immunology. 13. 829228–829228. 17 indexed citations

Mayer, Katharina A., Konstantin Doberer, Susanne Haindl, et al.. (2021). Diagnostic value of donor‐derived cell‐free DNA to predict antibody‐mediated rejection in donor‐specific antibody‐positive renal allograft recipients. Transplant International. 34(9). 1689–1702. 30 indexed citations

Eskandary, Farsad, Michael Dürr, Klemens Budde, et al.. (2019). Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial. Trials. 20(1). 37–37. 41 indexed citations

Battin, Claire, Annika De Sousa Linhares, Wolfgang Paster, et al.. (2019). Neuropilin-1 Acts as a Receptor for Complement Split Products. Frontiers in Immunology. 10. 2209–2209. 16 indexed citations

Herkner, Harald, Markus Wahrmann, Farsad Eskandary, et al.. (2017). Longitudinal assessment of HLA and MIC-A antibodies in uneventful pregnancies and pregnancies complicated by preeclampsia or gestational diabetes. Scientific Reports. 7(1). 13524–13524. 7 indexed citations

10.

Eskandary, Farsad, Gregor Bond, Heinz Regele, et al.. (2014). Late Antibody-Mediated Rejection in a Large Prospective Cross-Sectional Study of Kidney Allograft Recipients--Preliminary Results of the Screening Phase of the BORTEJECT Trial.. PubMed. 189–95. 9 indexed citations

11.

Eskandary, Farsad, Gregor Bond, Elisabeth Schwaiger, et al.. (2014). Bortezomib in late antibody-mediated kidney transplant rejection (BORTEJECT Study): study protocol for a randomized controlled trial. Trials. 15(1). 107–107. 41 indexed citations

12.

Morath, Christian, Luís Eduardo Becker, Albrecht Leo, et al.. (2012). ABO-Incompatible Kidney Transplantation Enabled by Non-Antigen-Specific Immunoadsorption. Transplantation. 93(8). 827–834. 47 indexed citations

13.

Böhmig, Georg A., Markus Wahrmann, & Gregor Bartel. (2011). Transplantation of the broadly sensitized patient. Current Opinion in Organ Transplantation. 16(6). 588–593. 9 indexed citations

14.

Bartel, Gregor, Katharina Walch, Markus Wahrmann, et al.. (2010). Prevalence and qualitative properties of circulating anti–human leukocyte antigen alloantibodies after pregnancy: No association with unexplained recurrent miscarriage. Human Immunology. 72(2). 187–192. 8 indexed citations

15.

Böhmig, Georg A., Gregor Bartel, Heinz Regele, & Markus Wahrmann. (2009). Prospects and limitations of post-transplantation alloantibody detection in renal transplantation. Human Immunology. 70(8). 640–644. 11 indexed citations

16.

Bartel, Gregor, Heinz Regele, Markus Wahrmann, et al.. (2008). Posttransplant HLA Alloreactivity in Stable Kidney Transplant Recipients—Incidences and Impact on Long-Term Allograft Outcomes. American Journal of Transplantation. 8(12). 2652–2660. 67 indexed citations

17.

Bartel, Gregor, Markus Wahrmann, Markus Exner, et al.. (2007). In Vitro Detection of C4d-Fixing HLA Alloantibodies: Associations With Capillary C4d Deposition in Kidney Allografts. American Journal of Transplantation. 8(1). 41–49. 48 indexed citations

18.

Wahrmann, Markus, Markus Exner, Heinz Regele, et al.. (2003). Flow cytometry based detection of HLA alloantibody mediated classical complement activation. Journal of Immunological Methods. 275(1-2). 149–160. 55 indexed citations

19.

Regele, Heinz, Markus Exner, Bruno Watschinger, et al.. (2001). Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrology Dialysis Transplantation. 16(10). 2058–2066. 193 indexed citations

20.

Haumer, Markus, et al.. (1999). Metabolism of Activated Complement Component C3 Is Mediated by the Low Density Lipoprotein Receptor-related Protein/α2-Macroglobulin Receptor. Journal of Biological Chemistry. 274(53). 38091–38096. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact